Page 142 - 71_04
P. 142
JUAN TAMARGO AN. R. ACAD. NAC. FARM.
nuevos fármacos sólo podrá conocerse tras realizar ensayos clínicos
controlados a largo plazo, en los que el objetivo primario sea la
morbimortalidad cardiovascular.
BIBLIOGRAFÍA
Fármacos hipolipemiantes
BONETTI, P. O.; LERMAN, L. O.; NAPOLI, C. y LERMAN, A. (2003): Statin effects beyond
lipid lowering-are they clinically relevant? Eur. Heart J. 24: 225-248.
CHEUNG, B. M.; LAUDER, I. J.; LAU, C. P. y KUMANA, C. R. (2004): Meta-analysis of
large randomized controlled trials to evaluate the impact of statins on cardio-
vascular outcomes. Br. J. Clin. Pharmacol. 57: 640-651.
Cholesterol Treatment Trialist’s Collaborators (2005): Efficacy and safety of choles-
terol-lowering treatment: prospective meta-analysis od data from 90056 partici-
pants in 14 randomised trials of statins. Lancet. 366: 1267-1278.
DARKES, M.; POOLE, R. y GOA, K. EZETIMIBE (2003): Am. J. Cardiovasc. Drugs. 3:
67-76.
DAVIDSON, M. H. y TOTH, P. P. (2004): Comparative effects of lipid-lowering thera-
pies. Prog. Cardiovasc. Dis. 47: 73-104.
DAVIGNON J. (2004): Beneficial cardiovascular pleiotropic effects of statins. Circula-
tion. 109 (Suppl 1): III 39-43.
DEAN, B. B.; BORENSTEIN, J. E.; HENNING, J. M.; KNIGHT, K. y MERZ, C. N. B. (2004):
Can change in HDL-cholesterol reduce cardiovascular risk? Am. Heart J. 147:
966-976.
ESC COMMITTEE FOR PRACTICE GUIDELINES (2003): To improve the quality of cli-
nical practice and patient care in Europe. 3rd. Joint European Societies’Task
Force on Cardiovascular Disease Prevention in Clinical Practice. 1-26.
LIMA, J.; FONOLLOSA, V. y CHACON, P. (2005): Selective cholesterol absorption inhibi-
tion as a new prospect in treatment of hypercholesterolemia. Med. Clin. (Barc)
125: 16-23.
MCKENNEY, J. M. (2005): Pharmacologic options for aggressive low-density lipopro-
tein cholesterol lowering: benefits versus risks. Am. J. Cardiol. 96 (4A: 60E-66E).
TOTH, P. (2004): High-density lipoprotein and cardiovascular risk. Circulation 109:
1809-1812.
VAN DER STEEG, W. A.; KUIVENHOVEN, J. A.; KLERKX, A. H.; BOEKHOLDT, S. M.; HOVINGH,
G. K. y KASTELEIN, J. J. (2004): Role of CETP inhibitors in the treatment of
dyslipidemia. Curr. Opin. Lipidol. 15: 631-636.
Aldosterona y Eplerenona
GARTHWAITE, S. M. y MCMAHON, E. G. (2004): The evolution of aldosterone antago-
nists. Mol. Cell. Endocrinol. 217: 27-31.
944
